
Slow-release micro tablets for the dietary management of phenylketonuria (PKU)

Afenil[®] Micro3H
Neutrafenil[®] micro R



afenil[®] micro3H

Phenylalanine-free amino acid mixture, indicated for the dietary management of hyperphenylalaninemia including phenylketonuria.

NUTRITIONAL INFORMATION		x 100 g
Energy	1678/396	kJ/kcal
Fats	3.6	g
of which saturated fatty acids	3.59	g
Carbohydrates	13	g
of which sugars	0	g
Fiber	3.7	g
Protein equivalent	70.7	g
Salt *	1	g
AMINO ACIDS		x 100 g
L-Alanine	3.07	g
L-Arginine	4.90	g
Ac. L-Aspartate	7.76	g
L-Cystine	2.01	g
Glycine	7.68	g
L-Glutamine	6.02	g
L-Isoleucine	5.31	g
L-Histidine	3.07	g
L-Leucine	8.27	g
L-Lysine	5.50	g
L-Methionine	1.42	g
L-Proline	5.54	g
L-Serine	3.42	g
L-Tyrosine	7.78	g
L-Threonine	5.31	g
L-Tryptophan	1.65	g
L-Valine	6.13	g
Taurine	0.12	g
L-Carnitine	0.08	g

neutrafenil[®] micro R

Phenylalanine-free LNAA (Large Neutral Amino Acids) mixture indicated for the dietary management of hyperphenylalaninemia, including phenylketonuria.

NUTRITIONAL INFORMATION		x 100 g
Energy	1686/399	kJ/kcal
Fats	5.3	g
of which saturated fatty acids	5.3	g
Carbohydrates	12	g
of which sugars	0	g
Fiber	5.8	g
Protein equivalent	70.79	g
Salt **	1.6	g
AMINO ACIDS		x 100 g
L-Arginine	1.92	g
L-Aspartate	4.95	g
L-Phenylalanine	–	g
L-Isoleucine	10	g
L-Histidine	3.36	g
L-Leucine	12	g
L-Lysine	5.44	g
L-Methionine	2.72	g
L-Tyrosine	24	g
L-Threonine	2.56	g
L-Tryptophan	8	g
L-Valine	10	g

* The salt content is due exclusively to the sodium in the product which equals 0.404 g/100 g

** The salt content is due exclusively to the sodium in the product which equals 0.65 g/100 g



1 CAP = 9 g OF PROTEIN EQUIVALENT

INDICATIONS AFENIL[®] MICRO 3H

Slow-release micro-tablets. Phenylalanine-free amino acid mixture, indicated for the dietary management of hyperphenylalaninemia including phenylketonuria. The micro-tablets are suitable for children over three years of age and adults.

INDICATIONS NEUTRAFENIL[®] MICRO R

Slow-release micro-tablets. Phenylalanine-free LNAA (Large Neutral Amino Acids) mixture with arginine and lysine, indicated for the dietary management of hyperphenylalaninemia, including phenylketonuria.

DOSAGE AND ADMINISTRATION

Dosage should comply with medical prescription, take subject's age, body weight and clinical condition into account and consider that micro-tablets are slow-release. The product releases the amino acids over three hours following intake. The cap of the jar contains ca. 13 g of micro-tablets (equal to approximately 9 g of protein equivalent).

INSTRUCTIONS FOR USE

Take the prescribed amount with water or other allowed liquids. The micro-tablets have no taste; to retain this feature, microtablets should not be chewed, pulverized, or dissolved.

STORAGE CONDITIONS

After use, close the jar well. Store in a cool, dry place, away from light and sources of direct heat. The date of minimum durability refers to the product in an unopened, correctly stored package.

IMPORTANT WARNINGS

The product must only be taken under medical supervision by individuals with known hyperphenylalaninemia, including phenylketonuria. The product must not be used as sole source of food. The product can result in health risks if consumed by individuals who do not have the specific disorder for which it is indicated. Keep out of the reach of children.



TASTELESS



EASY TO TRANSPORT



SLOW-RELEASE



EASY TO TAKE

The MICRO 3H range



Specific amino acid mixtures for the dietary management of:

■ PHENYLKETONURIA

■ GLUTARIC ACIDURIA type 1

■ UREA CYCLE
DISORDERS

■ HOMOCYSTINURIA

■ ISOVALERIC ACIDURIA

■ LEUCINOSIS

■ METHYLMALONIC/PROPIONIC
ACIDURIA

■ TYROSINEMIA TYPE 1

REFERENCES:

1. Fouillet H. *et al.* Absorption kinetics are a key factor regulating postprandial protein metabolism in response to qualitative and quantitative variations in protein intake - *Am J Physiol Regul Integr Comp Physiol* 297: R1691–R1705, 2009
2. Dangin M. *et al.* The digestion rate of protein is an independent regulating factor of postprandial protein retention - *Am J Physiol Endocrinol Metab* 280: E340–E348, 2001
3. Soni M.L., Kumar M. and Namdeo K.P. Sodium alginate microspheres for extending drug release: formulation and in vitro evaluation. *International Journal of Drug Delivery* 2 (2010) 64-68.
4. Giovannini M. *et al.* Randomized controlled trial of a protein substitute with prolonged release on the protein status of children with phenylketonuria. *J Am Coll Nutr.* 2014;33(2):103-10.
5. A. P. Burlina *et al.* Large Neutral Amino Acid Therapy Increases Tyrosine Levels in Adult Patients with Phenylketonuria: A Long Term Study. *Nutrients* 2019, 11, 2541.
6. A. P. Burlina *et al.* The Impact of a Slow-Release Large Neutral Amino Acids Supplement on Treatment Adherence in Adult Patients with Phenylketonuria. *Nutrients* 2020, 12, 2078;
7. Highlights from the Lunch session: New frontiers in the dietary treatment of PKU patients. *MediFormat Year XXV, N. 4, June 2020*
8. F. Porta *et al.* Tyrosine metabolism in health and disease: slow-release amino acids therapy improves tyrosine homeostasis in phenylketonuria. *J Pediatr Endocrinol Metab* 2020; 33(12): 1519-1523